Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2005.05.5160 on July 31 2006

Journal of Clinical Oncology, Vol 25, No 1 (January 1), 2007: pp. 57-63
© 2007 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weischer, M.
Right arrow Articles by Nordestgaard, B. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weischer, M.
Right arrow Articles by Nordestgaard, B. G.
Related Articles
Right arrowRelated Correspondence

Increased Risk of Breast Cancer Associated With CHEK2*1100delC

Maren Weischer, Stig Egil Bojesen, Anne Tybjærg-Hansen, Christen Kirk Axelsson, Børge Grønne Nordestgaard

From the Department of Clinical Biochemistry, Herlev University Hospital; Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital; The Copenhagen City Heart Study, Bispebjerg University Hospital; and Department of Breast Surgery, Herlev University Hospital, University of Copenhagen, Copenhagen, Denmark

Address reprint requests to Børge G. Nordestgaard, Professor and Chief Physician, Department of Clinical Biochemistry, Herlev University Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark; e-mail: brno{at}herlevhosp.kbhamt.dk

Purpose: CHEK2*1100delC heterozygosity has been associated with increased risk of breast, prostate, and colorectal cancer in case-control studies. We tested the hypothesis that CHEK2*1100delC heterozygosity in the general population increases the risk of cancer in general, and breast, prostate, and colorectal cancer in particular.

Patients and Methods: We performed a prospective study of 9,231 individuals from the Danish general population, who were observed for 34 years, and we performed a case-control study including 1,101 cases of breast cancer and 4,665 controls.

Results: Of the general population, 0.5% were heterozygotes and 99.5% were noncarriers. In the prospective study, multifactorially adjusted hazard ratios by CHEK2*1100delC heterozygosity versus noncarriers were 1.2 (95% CI, 0.7 to 2.1) for all cancers, 3.2 (95% CI, 1.0 to 9.9) for breast cancer, 2.3 (95% CI, 0.6 to 9.5) for prostate cancer, and 1.6 (95% CI, 0.4 to 6.5) for colorectal cancer. In the case-control study, age-matched odds ratio for breast cancer by CHEK2*1100delC heterozygosity versus noncarriers was 2.6 (95% CI, 1.3 to 5.4). The absolute 10-year risk of breast cancer in CHEK2*1100delC heterozygotes amounted to 24% in women older than 60 years undergoing hormone replacement therapy, with a body mass index of 25 kg/m2 or higher.

Conclusion: CHEK2*1100delC heterozygosity is associated with a three-fold risk of breast cancer in women in the general population.

published online ahead of print at www.jco.org on July 31, 2006.

Supported by the Michaelsen Foundation, the Danish Heart Foundation, Chief Physician Johan Boserup and Lise Boserups Fund, the Danish Medical Research Council, the Research Fund at Rigshospitalet, Copenhagen University Hospital, and Copenhagen County.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Related Correspondence

  • CHEK2 Mutation and Hereditary Breast Cancer
    Natalia Bogdanova, Sergei Feshchenko, Cezary Cybulski, and Thilo Dörk
    JCO 2007 25: 26 [Full Text]
  • CHEK2 Mutation and Hereditary Breast Cancer
    Natalia Bogdanova, Sergei Feshchenko, Cezary Cybulski, and Thilo Dörk
    JCO 2007 25: 26 [Full Text]
  • CHEK2 Screening: Do Not Think So Globally Yet
    Maria D. Iniesta and Sofia D. Merajver
    JCO 2008 26: 3092 [Full Text]


This article has been cited by other articles:


Home page
JCOHome page
S. L. Dombernowsky, M. Weischer, K. H. Allin, S. E. Bojesen, A. Tybjjrg-Hansen, and B. G. Nordestgaard
Risk of Cancer by ATM Missense Mutations in the General Population
J. Clin. Oncol., June 20, 2008; 26(18): 3057 - 3062.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. D. Iniesta and S. D. Merajver
CHEK2 Screening: Do Not Think So Globally Yet
J. Clin. Oncol., June 20, 2008; 26(18): 3092 - 3092.
[Full Text] [PDF]


Home page
JCOHome page
M. Weischer, S. E. Bojesen, C. Ellervik, A. Tybiaerg-Hanson, and B. G. Nordestgaard
In Reply
J. Clin. Oncol., June 20, 2008; 26(18): 3093 - 3094.
[Full Text] [PDF]


Home page
JCOHome page
M. Weischer, S. E. Bojesen, C. Ellervik, A. Tybjaerg-Hansen, and B. G. Nordestgaard
CHEK2*1100delC Genotyping for Clinical Assessment of Breast Cancer Risk: Meta-Analyses of 26,000 Patient Cases and 27,000 Controls
J. Clin. Oncol., February 1, 2008; 26(4): 542 - 548.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
K. Offit and J. E. Garber
Time to Check CHEK2 in Families With Breast Cancer?
J. Clin. Oncol., February 1, 2008; 26(4): 519 - 520.
[Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
M. Fatouros, G. Baltoyiannis, and D. H. Roukos
The Predominant Role of Surgery in the Prevention and New Trends in the Surgical Treatment of Women With BRCA1/2 Mutations
Ann. Surg. Oncol., January 1, 2008; 15(1): 21 - 33.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
N. Bogdanova, S. Feshchenko, C. Cybulski, and T. Dork
CHEK2 Mutation and Hereditary Breast Cancer
J. Clin. Oncol., July 1, 2007; 25(19): e26 - e26.
[Full Text] [PDF]


Home page
J. Exp. Med.Home page
D. D. Orsted, S. E. Bojesen, A. Tybjaerg-Hansen, and B. G. Nordestgaard
Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population
J. Exp. Med., June 11, 2007; 204(6): 1295 - 1301.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. A. Narod and H. T. Lynch
CHEK2 Mutation and Hereditary Breast Cancer
J. Clin. Oncol., January 1, 2007; 25(1): 6 - 7.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online